Research Article
Assessing the Short-Term Efficacy and Safety of Guselkumab for Moderate-to-Severe Plaque Psoriasis: Meta-Analysis of Randomized Controlled Trials
Table 1
Characteristics of RCTs included in this meta-analysis.
| | Authors (years) | NCT | Medications | Total () | Age (years) | Male, (%) | Time of follow-up (week) | Duration of psoriasis (year) | BSA (%) | PASI | DLOI |
| | Sofen 2014 [17] | NA | GUS 100 mg | 5 | NA | 4 (80) | 16 | NA | NA | NA | NA | | Placebo | 4 | NA | 3 (75) | NA | NA | NA | NA | | Gordon 2015 [16] | NCT01483599 | GUS 100 mg | 208 | 44.0 | 149 (72) | 16 | | | | NA | | Ada 40 mg | 43 | 50.0 | 30 (70) | | | | NA | | Placebo | 42 | 46.5 | 28 (67) | | | | NA | | Reich 2017 [18] | NCT02207244 | GUS 100 mg | 496 | | 349 (70.4) | 16 | | | | | | Ada 80 mg | 248 | | 170 (68.5) | | | | | | Placebo | 248 | | 173 (69.8) | | | | | | Blauvelt 2017 [19] | NCT02207231 | GUS 100 mg | 329 | | 240 (72.9) | 16 | | | | | | Ada 80 mg | 334 | | 249 (74.6) | | | | | | Placebo | 174 | | 119 (68.4) | | | | | | Nemoto 2018 [11] | NCT01484587 | GUS 100 mg | 5 | NA | 4 (80) | 16 | | | | NA | | Placebo | 4 | NA | 3 (75) | | | | NA | | Deodhar 2018 [12] | NCT02319759 | GUS 100 mg | 100 | | 52 (52) | 24 | | | | NA | | Placebo | 49 | | 24 (49) | | | | NA | | Ohtsuki 2018 [13] | NCT02325219 | GUS 100 mg | 63 | | 47 (74.6) | 16 | | | | | | Placebo | 64 | | 54 (84.4) | | | | |
|
|
